Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
7
×
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
7
×
detroit blog main
7
×
detroit top stories
indiana blog main
indiana top stories
life sciences
7
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
fda
cancer
eli lilly
amgen
bristol-myers squibb
drugs
fremanezumab
merck
nivolumab
novartis
teva pharmaceutical
alder biopharmaceuticals
What
new
7
×
drug
approval
bio
companies
fda
roundup
class
group
migraine
won
advantages
amgen
approved
arguments
bar
big
biogen’s
biopharma
biopharmaceutical
biotechs
brings
cancer
candidates
club
commercialized
competitors
congress
congressional
continued
convo
crispr
crop
decades
deeper
developed
dna
drugs
earlier
exceeded
Language
unset
Current search:
new
×
photo
×
" life sciences "
×
" clinical trials "
×
" detroit blog main "
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
IPO Wave Rolls On as Five Life Science Firms Haul in $651M
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines